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Abstract—Angiotensin II (Ang II) signaling in vascular smooth muscle cells (VSMCs) involves reactive oxygen species
(ROS) through unknown mechanisms. We propose that Ang II induces phosphorylation of growth signaling kinases by
redox-sensitive regulation of protein tyrosine phosphatases (PTP) in VSMCs and that augmented Ang II signaling in
spontaneously hypertensive rats (SHRs) involves oxidation/inactivation and blunted phosphorylation of the PTP, SHP-2.
PTP oxidation was assessed by the in-gel PTP method. SHP-2 expression and activity were evaluated by
immunoblotting and by a PTP activity assay, respectively. SHP-2 and Nox1 were downregulated by siRNA. Ang
II induced oxidation of multiple PTPs, including SHP-2. Basal SHP-2 content was lower in SHRs versus WKY. Ang
II increased SHP-2 phosphorylation and activity with blunted responses in SHRs. Ang II—induced SHP-2 effects were
inhibited by valsartan (AT1R blocker), apocynin (NAD(P)H oxidase inhibitor), and Nox1 siRNA. Ang II stimulation
increased activation of ERK1/2, p38MAPK, and AKT, with enhanced effects in SHR. SHP-2 knockdown resulted in
increased AKT phosphorylation, without effect on ERK1/2 or p38MAPK. Nox1 downregulation attenuated Ang
II–mediated AKT activation in SHRs. Hence, Ang II regulates PTP/SHP-2 in VSMCs through AT1R and Nox1-based
NAD(P)H oxidase via two mechanisms, oxidation and phosphorylation. In SHR Ang II–stimulated PTP oxidation/
inactivation is enhanced, basal SHP-2 expression is reduced, and Ang II–induced PTP/SHP-2 phosphorylation is
blunted. These SHP-2 actions are associated with augmented AKT signaling. We identify a novel redox-sensitive
SHP-2–dependent pathway for Ang II in VSMCs. SHP-2 dysregulation by increased Nox1-derived ROS in SHR is
associated with altered Ang II–AKT signaling. (Circ Res. 2008;103:149-158.)
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Reactive oxygen species (ROS), ubiquitous reactivederivatives of O2 metabolism that include superoxide
anion (O2) and hydrogen peroxide (H2O2), are produced
primarily by nonphagocytic NAD(P)H oxidase (Nox) in
the vasculature.1,2 This enzyme, of which 4 of the 7
isoforms have been detected in rat vascular cells (Nox1,
Nox2, Nox4 and Nox5),3,4 is regulated by vasoactive
peptides, including angiotensin II (Ang II).1–3 In hyperten-
sion, increased ROS production leads to vascular smooth
muscle cell (VSMC) growth and inflammation through
increased activation of c-Src, mitogen-activated protein
(MAP) kinases, and PI3K/AKT.5,6
ROS influence many signaling events, mainly through
oxidative modification of proteins. Of the many redox-
sensitive targets, including protein kinases (MEKK1, PKA,
CaM-kinases, c-Src), small G proteins (Rac, Rho), ion chan-
nels (Ca2-channels), and transcription factors (AP-1, NF-
B), protein tyrosine phosphatases (PTPs) are particularly
important because they possess a conserved 230 amino acid
domain with a reactive and redox-regulated thiol-containing
cysteine, which when oxidized makes the protein inactive.9,10
Typically, prooxidative events are correlated with activation
of signaling molecules.11 Paradoxically, many of the direct
oxidation events are inhibitory, blocking activity of target
molecules. Protein tyrosine phosphatases play a critical role
in the reversible phosphorylation of proteins, where they
remove phosphates from downstream substrates thereby
counterbalancing effects of protein tyrosine kinases (PTK).
In addition to posttranslational modification by oxidation,
PTPs are regulated by tyrosine (or serine) phosphorylation,12
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which renders the protein active. Both thiol oxidation and
tyrosine phosphorylation are reversible and dynamic, and
both modifications can occur in response to the same stimu-
lus. Whereas tyrosine phosphorylation is usually associated
with enzyme activation, oxidation leads to PTP inactivation.
Mechanisms of interplay between phosphorylation and oxi-
dation and functional implications of such crosstalk remain
unclear, but changes in the local redox environment may
fine-tune PTP phosophorylation and consequent downstream
signaling.13,14
Ang II, through ROS, induces activation of RTKs such as
EGFR and PDGFR- as well as nonreceptor tyrosine kinases,
Figure 1. Ang II induces rapid oxidation of multiple PTP in VSMCs. Lysates were prepared under anaerobic conditions in the pres-
ence of 10 mmol/L IAA and subjected to the in-gel PTP assay. Top panels represent the in-gel PTP activity assay visualized by
autoradiography. Arrowheads indicate the PTPs that were oxidized and arbitrarily called oxidized PTP (OxP)1, OxP2, and OxP3.
Bar graphs represent quantification of multiple immunoblots for the indicated PTPs. Data are meansSEM of 3 to 4 experiments.
*P0.05 vs control (Ctl).
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such as c-Src, which interact with numerous PTPs, including
SHP-2, to regulate cell function.15,16 Activated SHP-2 de-
phosphorylates substrates that, directly or indirectly, have an
inhibitory role in MAP kinase and PI3K/AKT signaling.17 In
cultured VSMCs, oxidative inhibition of PTP is an intrinsic
component of H2O2 and PDGF-induced signaling, an effect
that is reversed by antioxidant treatment.18 In Chinese ham-
ster ovary (CHO) cells stably expressing a rat vascular
angiotensin II type 1A receptor (CHO-AT[1A]), Ang II
induced rapid and reversible tyrosine phosphorylation of
the PTP SHP-2, which was associated with increased
cyclin D1 expression in a PI3K/AKT and MAP kinase-
dependent manner.19
The exact role of ROS in Ang II–mediated regulation of
PTP/SHP-2 and associated kinase signaling in vascular cells
remains unclear. We tested the hypothesis that in VSMCs,
activation of growth signaling kinases by Ang II involves
redox-sensitive regulation of the PTP SHP-2 and that in
hypertension enhanced growth signaling is attributable to
SHP-2 dysregulation. We also evaluated the role of AT1R,
AT2R, and NADPH oxidase in these processes. Findings from
our study demonstrate that in VSMCs Ang II regulates
PTP/SHP-2 through 2 mechanisms, oxidation and phosphor-
ylation. In SHR, signaling through AKT, but not ERK1/2 or
p38MAPK, is associated with increased oxidation and
blunted phosphorylation of SHP-2. Such events are mediated
through AT1R-regulated Nox1-based NADPH oxidase. These
novel data highlight the importance of ROS in oxidation/
phosphorylation interplay in PTP/SHP-2 signaling by Ang II
in VSMCs.
Materials and Methods
Cell Culture
VSMCs from mesenteric resistance arteries (important in peripheral
resistance and in blood pressure regulation) from 16-week-old WKY
and SHR rats were isolated and cultured as before described.7 Low
passaged cells rendered quiescent in serum-free medium for 24 hours
were used.
In-Gel Phosphatase Assay
The in-gel PTP assay was performed as described by Meng et al.20
After stimulation with Ang II (107 mol/L, 0 to 60 minutes), cells
were lysed under anaerobic conditions to prevent spontaneous
oxidation of PTPs through the air oxygen. Lysates (30 g) were
subjected to an in-gel phosphatase activity assay21 using SDS-PAGE
gels containing [-32P]-labeled poly (4:1) Glu-Tyr substrate
(1.5106 cpm/20 mL of gel solution, 2 mol/L p-Tyr).
Analysis of Oxidized SHP-2 Using the
oxPTP Antibody
An oxPTP antibody was used to detect reversible oxidation of PTPs
derived from cell extracts. The oxPTP antibody was developed to
specifically recognize the sulfonic acid form of catalytic site cys-
teines of PTPs.22,23 VSMCs were stimulated with Ang II (107
mol/L, 5 and 10 minutes) and H2O2 (100 mol/L, 10 minutes) and
lysed in a lysis buffer with or without 30 mmol/L IAA. SHP-2 PTP
was collected by immunoprecipitation using anti-SHP-2 antibody.
Signals were visualized by chemiluminescence.
Western Blot Analysis of SHP-2 Expression
and Phosphorylation
VSMCs from WKY and SHR rats were stimulated with Ang II (107
mol/L, 5 minutes). Expression and phosphorylation of SHP-2 was
measured by immunoblot. In some experiments, cells were pre-
treated with apocynin (NAD(P)H oxidase inhibitor; 105 mol/L, 3
hours), valsartan (AT1 receptor [AT1R] blocker; 105 mol/L, 30
minutes) or PD123319 (AT2R blocker; 105 mol/L, 30 minutes).
Expression and phosphorylation of SHP-2 were measured by West-
ern blot.
SHP-2 PTP Activity Assay
VSMCs were stimulated with Ang II (107 mol/L, 5 minutes) in the
absence or presence of the ROS scavenger tiron (105 mol/L, 30
minutes preincubation) or apocynin (105 mol/L, 3 hours preincuba-
tion) and activity of SHP-2 measured using a PTP activity assay as
described.24
SHP-2 and Nox 1 siRNA Transfection Studies
VSMCs were transiently transfected with small interfering RNAs
(siRNA) against rat SHP-2 and rat Nox 1 (QIAGEN Inc). The siRNA
sequences for SHP-2 are available online. Cells were seeded at a
density of 2.5105 cells per well in 60-mm plates and exposed to
either transfectant alone (HiPerFect Transfection Reagent) or siRNA
targeting SHP-2 or Nox 1 as described.25 A nonsilencing siRNA
oligonucleotide sequence (NS siRNA) that does not recognize any
known homology to mammalian genes was used as a negative
control. After transfection, gene silencing was monitored at the
protein levels by immunoblotting using anti–SHP-2 and anti–Nox 1
antibodies. Control cells were exposed to transfectant in the absence
of siRNA.
An expanded Materials and Methods section is available online at
http://circres.ahajournals.org.
Statistical Analysis
Data are presented as meanSEM. Groups were compared using
1-way ANOVA or Student t test as appropriate. Newman–Keuls Post
test was used to compensate for multiple testing procedures. P0.05
was significant.
Results
Ang II Induces Reversible Oxidation of
Multiple PTPs
The reversible oxidation of various PTPs after Ang II
stimulation was assessed by a modified in-gel PTP assay.
Only activity of those PTPs susceptible to ROS-induced
oxidation are recovered and visualized by the appearance of
a clear white area of dephosphorylation, surrounding the
position of the PTP in the gel on the black background of
Figure 2. Ang II induces oxidation of SHP-2 in VSMCs. VSMCs
from WKY were stimulated with Ang II (107 mol/L for 5 and 10
minutes) or H2O2 (100 mol/L for 10 minutes) and lysed with or
without IAA as indicated. SHP-2 was immunoprecipitated from
cell lysate and subjected to pervanadate treatment. Immunopre-
cipitated SHP-2 was analyzed by consecutive immunoblotting
with oxPTP and SHP-2 antibodies.
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radioactivity labeled substrate. As shown in Figure 1, multi-
ple oxidized PTPs, of varying molecular size, are present in
VSMCs. We have arbitrarily named the 3 prominent proteins
as oxidized PTP (OxP) 1, OxP2, and OxP3. Ang II (107
mol/L, 0 to 30 minutes) stimulation resulted in rapid oxida-
tion of multiple PTPs corresponding to OxP1 and OxP3. In
SHR cells oxidation of OxP1 and OxP3 was significantly
increased (P0.05) after 5 minutes and 15 minutes of Ang II
stimulation, respectively. In WKY cells oxidation of OxP3
tended to be increased at 30 minutes. Our results demonstrate
the potential for Ang II–mediated ROS generation to induce
oxidation and inactivation of PTPs particularly in VSMCs
from SHR. As a positive control, VSMCs were also stimu-
lated with H2O2, which induced oxidation of multiple PTPs
(see supplemental Figure I).
Detection of SHP-2 PTP Oxidation by Ang II
Using an oxPTP Antibody
Using a novel antibody-based method,22 we assessed whether
one of the PTPs regulated by Ang II could be SHP-2. This
procedure involves alkylation of reduced PTPs with IAA,
pervanadate-induced oxidation to sulfonic acid forms of
reversibly oxidized PTPs, and detection of oxidized SHP-2 by
immunoprecipitation with oxPTP antibody. To increase the
efficiency of pervanadate oxidation of reversibly oxidized
PTPs, samples were reduced by incubation with DTT. As
shown in Figure 2 oxidation of SHP-2 in the basal state is
very low. After Ang II stimulation, SHP-2 oxidation was
markedly increased. H2O2-stimulated (100 mol/L, 10 min-
utes) cells were used as a positive control.
Expression and Phosphorylation of SHP-2 in
WKY and SHR VSMCs
Lower basal expression (P0.01) and phosphorylation
(P0.05) of SHP-2 was observed in SHR cells compared to
WKY cells (Figure 3A). Ang II increased SHP-2 phosphor-
ylation in WKY (P0.001) and SHR (P0.05) cells. How-
ever, the magnitude of Ang II–induced SHP-2 phosphoryla-
tion was lower in cells from SHR versus WKY (Figure 3B).
Figure 3. Expression and phosphorylation of SHP-2 in VSMCs from WKY and SHR rats. A, Basal expression and phosphorylation of
SHP-2 were determined by Western blotting. B, Cells were stimulated with Ang II (107 mol/L, 5 minutes) and phosphorylation of
SHP-2 was examined by immunoblotting. Membranes were stripped and reprobed with -actin antibody. Bar graphs represent quantifi-
cation of multiple immunoblots. Data are presented as meansSEM of 5 to 6 experiments. *P0.05, **P0.01, ***P0.001 vs WKY or
control (Ctl).
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Ang II Regulation of SHP-2 Is Mediated Through
AT1R and via NAD(P)H Oxidase-Derived ROS
To evaluate possible mechanisms whereby Ang II regulates
SHP-2, VSMCs from WKY rats were exposed to the AT1R
blocker valsartan, the AT2R blocker PD123319, and to the
NAD(P)H oxidase inhibitor apocynin, before Ang II stimu-
lation. Ang II–induced phosphorylation of SHP-2 was signif-
icantly diminished by preincubation of cells with valsartan
(P0.05; Figure 4A) and apocynin (P0.05; Figure 4C).
PD123319 did not influence Ang II–induced SHP-2 phos-
phorylation (Figure 4B). These results suggest that Ang
II–dependent regulation of SHP-2 is mediated through AT1R
and via NAD(P)H oxidase-generated ROS. Neither valsartan,
PD123319, nor apocynin influenced basal SHP-2 status.
To investigate in further detail whether Nox1 is the
NAD(P)H oxidase isoform involved in SHP-2 phosphoryla-
tion by Ang II, we transiently downregulated Nox1 expres-
sion using siRNA and assessed phosphorylation of SHP-2. As
observed in Figure 4D, Ang II–induced phosphorylation of
SHP-2 was reduced to basal levels in Nox1 transfected cells
compared with control cells (exposed to transfectant without
siRNA) and to nonsilencing siRNA transfected cells. These
results, together with the apocynin data, suggest that Nox1-
based NAD(P)H oxidase-derived ROS plays an important
role in SHP-2 regulation by Ang II in VSMCs.
Treatment of VSMCs With Tiron and Apocynin
Increases Ang II–Induced SHP-2 PTP Activity in
SHR Cells
Using a PTP activity assay to directly measure activity of
SHP-2, we investigated whether SHP-2 activity is differen-
tially regulated in SHRs compared with WKY and whether
ROS are important in regulating SHP-2 activity. SHP-2 PTP
activity was measured in WKY and SHR cells stimulated
with Ang II (107 mol/L, 5 minutes) in the absence or
presence of apocynin and the ROS scavenger tiron. Ang II
induced a 30% increase in SHP-2 PTP activity in WKY cells
only (Figure 5A). Whereas in WKY, apocynin and tiron
preincubation decreased Ang II–induced activation of SHP-2
to basal levels (Figure 5A), both apocynin (P0.01) and tiron
(P0.05) preincubation increased SHP-2 activity in Ang
II–stimulated SHR cells (Figure 5B). These results suggest
that in SHR VSMCs, only when ROS bioavailability is
reduced is SHP-2 activity increased.
Knockdown of SHP-2 Expression in VSMCs
Increases Ang II–Induced Activation of AKT but
not of ERK1/2 and p38MAP Kinase
Using RNA interference, we evaluated whether SHP-2
knockdown affects ERK1/2, p38 MAP kinase, and AKT
activation by Ang II in VSMCs. As shown in Figure 6, SHP-2
suppression was observed after 24 hours, 48 hours, and 72
hours of incubation with siRNAs. Because the knockdown of
SHP-2 was efficient after 24 hours (P0.001), we used this
time point for further experiments. The functional signifi-
cance of SHP-2 oxidation was evaluated by assessing signal-
ing growth responses to Ang II in SHP-2 knockdown cells.
We treated cells with Ang II and analyzed the activation of
downstream signaling pathways after downregulating SHP-2
with SHP-2 siRNA (Figure 7). Short-term (5 minutes) expo-
sure to Ang II (107 mol/L) induced an increase (P0.05) in
ERK1/2 phosphorylation (Figure 7A), p38MAP kinase phos-
phorylation (Figure 7B), and AKT phosphorylation (Figure
7C). Using RNA interference, knockdown of SHP-2 was
associated with a significant increase in Ang II–induced
phosphorylation of AKT in WKY and SHR cells but did not
affect ERK1/2 and p38MAP kinases phosphorylation. These
results suggest that SHP-2 negatively regulates Ang II acti-
vation of AKT pathways in VSMCs. ERK1/2, p38MAP
kinase, and AKT phosphorylation were similar in control,
siRNA-transfected, and NS siRNA-transfected cells. Protein
levels of -actin were unaffected by siRNA transfection.
Figure 4. Phosphorylation of SHP-2 by Ang II is mediated through AT1R and NAD(P)H oxidase. VSMCs from WKY were pretreated with
(A) Valsartan (Val, 105 mol/L) for 30 minutes, (B) PD123319 (PD, 105 mol/L) for 30 minutes or (C) Apocynin (Apo, 105 mol/L) for 3
hours and stimulated with Ang II (107 mol/L, 5 minutes). SHP-2 phosphorylation was determined by Western blot. Total loading was
determined by reprobing membranes with -actin antibody. Left panels are representative Western blots of SHP-2 phosphorylation. Bar
graphs represent quantification of multiple immunoblots. Data are presented as meansSEM of 3 to 4 experiments. *P0.05 vs Ang II,
**P0.01 vs control (Ctl). D, VSMCs from WKY were transfected with Nox 1 siRNA or nonsilencing (NS) siRNA for 72 hours before
stimulation with Ang II (107 mol/L, 5 minutes). Control cells were exposed to the transfectant without siRNA. SHP-2 phosphorylation
was determined by Western blotting. Membranes were stripped and reprobed with SHP-2 antibody.
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Knockdown of Nox 1 Expression in VSMCs
Decreases Ang II–Induced Activation of AKT in
SHR Cells
VSMCs were transfected with Nox1 siRNA for 24 hours, 48
hours, and 72 hours. Maximal downregulation of Nox1
expression was observed after 72 hours of transfection
(Figure 8A). To investigate whether knockdown of Nox1
expression by RNA interference decreases Ang II–induced
activation of AKT, SHR and WKY VSMCs were stimulated
with Ang II for 5 and 10 minutes and AKT phosphorylation
was measured in nontransfected cells, in NS siRNA-
transfected cells, and in Nox1 siRNA-transfected cells. Ang
II induced an increase in AKT phosphorylation by 127% in
WKY cells versus 161% in SHR cells (Figure 8B and 8C).
Nox 1 siRNA-transfected SHR VSMCs but not WKY cells
showed a significant decrease in Ang II–induced phosphor-
ylation of AKT after 5 minutes (P0.01) and 10 minutes
(P0.05) of stimulation.
Discussion
Major findings from the present study demonstrate that (1)
Ang II regulates PTP/SHP-2 in VSMCs through 2 redox-
sensitive mechanisms, oxidation and phosphorylation; (2)
Ang II–induced activation of SHP-2 is mediated via AT1R
and Nox1-based NAD(P)H oxidase-derived ROS; (3)
VSMCs from SHR exhibit increased oxidation/inactivation
and blunted redox-sensitive phosphorylation/activation of
SHP-2; and (4) increased signaling through AKT, but not
through ERK1/2 or p38MAP kinase, by Ang II is induced via
Nox1-SHP-2-dependent processes. These novel data high-
light the importance of ROS in PTP/SHP-2 signaling by Ang
II in VSMCs and suggest that enhanced NAD(P)H oxidase–
mediated ROS generation in SHR, as we previously report-
ed,26,27 may contribute to impaired interplay between oxida-
tion/phosphorylation and dysregulation of PTP/SHP-2, which
leads to hyperactivation of downstream AKT signaling path-
ways. This differential regulation may play a role in redox-
sensitive vascular remodeling in hypertension.
Ang II is a multifunctional hormone influencing many
cellular processes involved in the regulation of vascular
function, including proliferation, migration, and inflamma-
tion.28 The pleiotropic vascular effects are mediated in large
part through NAD(P)H oxidase-driven generation of ROS,
which function as intracellular and intercellular second mes-
sengers to modulate downstream signaling molecules, such as
PTPs.29,30 PTPs are a large, structurally diverse family of
which SHP-2, a 68-kDa nontransmembrane-type PTP also
known as PTP1D, PTP2C, Syp, and SH-PTP2, appears to be
critical in regulating cardiovascular cells.31
Despite the importance of PTPs in VSMC signaling, there
is a paucity of information on its regulation and little is
known about mechanisms whereby Ang II influences these
Figure 5. Treatment of cells
with tiron and apocynin
increases Ang II–induced
SHP-2 PTP activity in SHR
cells. WKY (A) and SHR
(B) VSMCs were stimulated
with Ang II (107mol/L, 5
minutes) in the presence or
absence of tiron (105
mol/L, 30 minutes preincu-
bation) or apocynin (105
mol/L, 3 hours preincuba-
tion). SHP-2 was immuno-
precipitated with anti–
SHP-2 antibody. The
immune complexes were
subjected to 20 mmol/L
pNPP and the PTP activity
was determined by measur-
ing the absorbance of the
supernatant at 410 nm. Bar
graphs represent quantifica-
tion of multiple PTP assays; bottom blots show endogenous SHP-2 immunoprecipitated by the antibody. *P0.05, **P0.01 vs
Ang II and ***P0.001 vs control (Ctl).
Figure 6. SHP-2 siRNA downregulates SHP-2 expression in
WKY (A) and SHR VSMCs (B). VSMCs were transfected with
SHP-2 siRNA (24, 48, and 72 hours) or nonsilencing (NS) siRNA
(72 hours) and SHP-2 protein expression was assessed by im-
munoblotting. Control cells were exposed to transfectant with-
out siRNA. Membranes were stripped and reprobed with -actin
antibody. Data are expressed as SHP-2:-actin ratio and
expressed as meanSEM of 3 experiments. *P0.01 and
**P0.001 vs control (Ctl).
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phosphatases in VSMCs. Because of their particular struc-
ture, PTPs are susceptible to oxidation and consequent
inactivation by ROS.32 Oxidation of PTPs inhibits the nucleo-
philic property of the PTP which is required for substrate
dephosphorylation. Using the in-gel PTP assay we demon-
strate that Ang II induces an increase in the reversible
inactivation of multiples PTPs of different molecular weights
in SHR VSMCs. In support of our findings, others have
shown that cell stimulation by PDGFR, EGFR, insulin
receptor, and FGFR produces H2O2, which reduces PTP
activity.33,34 Lee and colleagues34 demonstrated that EGF-
induced PTP1B inactivation is dependent on reversible oxi-
dation of cysteine residues by H2O2. This is particularly
important with respect to Ang II, which mediates many of its
signaling events in vascular cells through EGFR transactiva-
tion.35 Besides H2O2, other ROS may inactivate PTPs by
oxidation. Recent studies suggest that PTP1B may be more
efficiently regulated by O2 than by H2O2.36
To further evaluate how Ang II regulates PTPs, we used an
antibody-based method to identify a putative PTP that is
specifically oxidized by Ang II stimulation in VSMCs. Using
this approach, we demonstrate for the first time that Ang
Figure 7. Effects of SHP-2 knockdown on Ang II–induced acti-
vation of ERK1/2 (A), p38MAP kinase (B), and AKT (C). VSMCs
were transfected with SHP-2 siRNA or nonsilencing (NS) siRNA
for 24 hours and cell extracts were analyzed by immunoblotting
using phospho-specific anti-ERK1/2, antip38MAP kinase, anti-
AKT antibodies. Membranes were stripped and reprobed with
anti–SHP-2 and anti– actin antibodies. Data are represented
as the meanSEM of 3 experiments. *P0.05, **P0.01,
***P0.001 vs control (Ctl) and #P0.05, ##P0.001 vs Ang II.
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II–derived ROS production regulates, by oxidation, SHP-2
PTP (Figure 2). Meng et al20 previously reported that SHP-2
is reversibly oxidized by other stimuli such as PDGF-BB in
RAT-1 cells.
In addition to regulating PTP/SHP-2 by oxidation, we
show that VSMC SHP-2 content differs between SHR and
WKY and that Ang II stimulation induces significant phos-
phorylation/activation of SHP-2. In nonstimulated VSMCs
the expression and phosphorylation of this tyrosine phospha-
tase is downregulated in VSMCs from SHRs compared with
WKY. Ang II regulates SHP-2 by increasing its phosphory-
lation in both WKY and SHR cells with a blunted effect in
SHR cells. To evaluate mechanisms whereby Ang II influ-
ences SHP-2, VSMCs were exposed to the AT1R blocker,
valsartan, the AT2R blocker PD123319, and the NAD(P)H
oxidase inhibitor apocynin before Ang II stimulation. Using
these pharmacological tools we show that Ang II–mediated
phosphorylation of SHP-2 involves the AT1R as previously
reported37 and activation of NAD(P)H oxidase. Using siRNA
to Nox1, we have extended these findings to demonstrate that
the Nox1 isoform of the NAD(P)H oxidase family is involved
in Ang II phosphorylation of SHP-2 in VSMCs. Nox1 is
present in VSMCs and its expression and activity are in-
creased in hypertension.38,39
SHP-2 tyrosine phosphorylation and its phosphatase activ-
ity have not been fully characterized in Ang II–mediated
redox signaling. In this study, we showed that ROS are
important in regulating VSMC SHP-2, particularly in SHR.
This is evidenced by our findings that inhibition of NAD(P)H
oxidase–derived ROS by apocynin or ROS scavenging by
tiron increased Ang II–mediated SHP-2 activity in SHR cells,
indicating that when ROS bioavailability is reduced, SHP-2
activity is increased. Downregulation of basal SHP-2 expres-
sion and phosphorylation as well as blunted Ang II–induced
SHP-2 phosphorylation and activity in SHR may contribute
to altered vascular signaling in hypertension.
Exact functions of vascular SHP-2 await elucidation.40 In
stable cell lines overexpressing wild-type SHP-2, SHP-2
dephosphorylated focal adhesion-associated proteins includ-
ing paxillin, p130Cas, and tensin with associated decreased
numbers of focal adhesions within cells.41 These data indicate
a role for SHP-2 in the regulation of the cellular architecture
of VSMCs, suggesting that this phosphatase might be instru-
mental in vascular remodeling.41 In SHP-2 overexpressing
VSMCs, Ang II–induced activation of c-Src and ERK1/2 was
abrogated.42 Here we investigated the functional significance
of Ang II–regulated SHP-2 by examining effects of Ang II on
downstream growth and cell survival signaling pathways in
VSMCs in which SHP-2 was downregulated. Our data
demonstrate that SHP-2 knockdown by siRNA significantly
increased Ang II–induced phosphorylation of AKT in both
WKY and SHR cells, suggesting that SHP-2 negatively
regulates Ang II activation of the AKT pathway in VSMCs.
Others have shown a positive relationship between SHP-2
and AKT signaling.43 Reasons for these conflicting data may
relate to the fact the SHP-2 may act as a dual modulator of
downstream signaling targets.44 Catalytic activity of SHP-2 is
required for insulin-like growth factor (IGF-1)–induced acti-
vation of AKT in VSMCs.43–45 Unlike other studies, which
were performed in cell lines overexpressing SHP-2, we could
not demonstrate a role for SHP-2 in ERK1/2 regulation.
These conflicting data may relate to the fact that we used
Figure 8. Effects of Nox1 knockdown using siRNA on Ang II–induced AKT acti-
vation in WKY and SHR VSMCs. A, VSMCs were transfected with Nox1 siRNA
(24, 48, and 72 hours) or nonsilencing (NS) siRNA for 72 hours. Phosphoryla-
tion of AKT and expression of Nox1 in WKY (B) and SHR (C) VSMCs were
determined by Western blot. Control cells were exposed to transfectant with-
out siRNA. Membranes were stripped and blotted with anti– actin antibody.
Data are expressed as Nox1:-actin ratio and expressed as the meanSEM of
4 to 6 independent experiments. *P0.05, ***P0.001 vs control (Ctl); #P0.05 vs Ang II 10 minutes and ##P0.01 Ang II 5
minutes.
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VSMCs derived from primary cultures versus cell lines and
that in different conditions SHP-2 differentially regulates
downstream kinases, as shown by Doan et al,42 where SHP-2
negatively regulated MAP kinases without effect on Jak2
tyrosine phosphorylation or Fyn catalytic activity. It may also
be possible that in our experimental paradigm other PTPs,
such as PTPB1 and MAPK phosphatase, regulate ERK1/2
and p38MAP kinase. Taken together it is becoming increas-
ingly apparent that SHP-2 exhibits specific substrate speci-
ficity depending on the cell type and the nature of the agonist.
AKT regulates cellular functions such as migration, pro-
liferation, differentiation, and apoptosis and is critically
involved in PI3K-mediated cell survival.46,47 Activation of
AKT signaling is sufficient to block cell death induced by
apoptotic stimuli, and transduction of dominant negative
AKT inhibits growth factor-induced cell survivor.48 AKT
regulates cell cycle and cellular senescence by modulating
cell cycle proteins such us E2F, p21, MDM2, and human
telomerase reverse transcriptase subunit (hTERT).49 AKT
also enhances protein synthesis through increasing the phos-
phorylation of eukaryotic initiation factor 4E-binding protein
1 (4E-BP1) and S6 kinase.50 With respect to the role of AKT
in vascular homeostasis and angiogenesis, results obtained in
our study are relevant because they link Ang II/AT1R/AKT
signaling through redox-sensitive SHP-2, which is important
in cross-talk with RTK-mediated PI3-K/AKT activation and
vascular remodeling.51 Of significance we found that Ang
II–induced phosphorylation of AKT in SHR is dependent on
Nox1-induced ROS because AKT phosphorylation was sig-
nificantly decreased in Nox1 siRNA transfected SHR
VSMCs but not WKY cells. Considering that vascular Nox1-
derived ROS is increased in hypertension, it may be possible
that vascular changes associated with oxidative stress in SHR
are linked to dysregulation of redox-sensitive SHP-2 and
altered AKT signaling.
In summary, findings from our study demonstrate that Ang
II, through redox-sensitive processes, regulates multiple vas-
cular PTPs, among which SHP-2 PTP is important. We
identify 2 mechanisms whereby Ang II modulates PTP/
SHP-2, by oxidation and by phosphorylation. In SHR, sig-
naling through AKT, but not ERK1/2 or p38MAPK, is
associated with increased oxidation and blunted phosphory-
lation of SHP-2. Such processes are mediated through AT1R-
regulated Nox1-based NADPH oxidase. Collectively our data
highlight the importance of ROS in oxidation/phosphoryla-
tion interplay in PTP/SHP-2 signaling by Ang II in VSMCs
and identify a novel redox-sensitive SHP-2-dependent path-
way that regulates AKT signaling in SHR.
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